1344 - Is change to another treatment immediately after failure of gefitinib recommended in patients harboring activating epidermal growth factor receptor...

Date 28 September 2012
Event ESMO Congress 2012
Session Publication Only
Topics Anti-Cancer Agents & Biologic Therapy
Non-Small-Cell Lung Cancer, Metastatic
Presenter Kazuhiro Asami
Authors K. Asami1, T. Okuma2, T. Hirashima3, M. Kawahara4, T. Kawaguchi5, K. Okishio5, N. Omachi6, N. Takeuchi1
  • 1Clinical Oncology, Kinki-chuo Chest Medical Center, 591-8555 - Sakai/JP
  • 2Radiology, Kinki-chuo Chest Medical Center, 591-8555 - sakai/JP
  • 3Department Of Thoracic Malignancy, Osaka Prefectural Medical Center for Respiratory and Allergic diseases, JP- 583-8588 - Osaka/JP
  • 4Clinical Oncology, Federation of National Public Service Personnel Mutual Aid Associations, Otemae Hospital, 540-0008 - osaka/JP
  • 5Internal Medicine, Kinki-Chuo Chest Medical Center, 591-8555 - Sakai-City/JP
  • 6Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, 591-8555 - Sakai/JP



Gefitinib is an effective agent for use in treating patients suffering from non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations. However, no optimal strategies have been established for treating these patients after gefitinib fails. Here, we conducted a retrospective study to assess the survival benefit of continued gefitinib treatment in these cases.

Patients and methods

We analyzed gefitinib responders with activating EGFR mutations who developed progressive disease (PD) during the course of therapy. Prognostic variables were analyzed using a Cox proportional-hazards model.


Among the 146 patients retrospectively reviewed, exon-19 deletion mutations and L858R point mutations were detected in 78 and 68 patients, respectively. Median survival time after PD confirmation was 14.9 months (95% confidence interval [CI]: 7.9-21.9), and the median duration of continued gefitinib therapy beyond PD was 3.4 months. Statistical analysis showed that good performance status (0-1) (hazard ratio [HR]: 0.7), progression of previously evaluated lesion (HR: 0.6), and at least 3 months of continued treatment (HR: 0.4) were independent prognostic factors.


Continuation of gefitinib beyond PD is an effective optional treatment in EGFR-mutated patients.


All authors have declared no conflicts of interest.